Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 Diabetes

Q2 Medicine

Clinical Diabetes Pub Date : 2024-04-17 DOI:10.2337/cd23-0107

Roy W. Beck, Carol J Levy, Y. C. Kudva, Keta Pandit, Thomas Blevins, Dan Raghinaru, J. Pinsker

引用次数: 0

查看原文本刊更多论文

胰高血糖素样肽 1 (GLP-1) 受体激动剂与 Control-IQ 技术配合使用对 2 型糖尿病的益处

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Diabetes Medicine-Internal Medicine

CiteScore

4.30

自引率

0.00%

发文量

期刊介绍： The mission of Clinical Diabetes is to provide primary care providers and all clinicians involved in the care of people with diabetes with information on advances and state-of-the-art care for people with diabetes. Clinical Diabetes is also a forum for discussing diabetes-related problems in practice, medical-legal issues, case studies, digests of recent research, and patient education materials.